SG11201910043PA - Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof - Google Patents
Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereofInfo
- Publication number
- SG11201910043PA SG11201910043PA SG11201910043PA SG11201910043PA SG 11201910043P A SG11201910043P A SG 11201910043PA SG 11201910043P A SG11201910043P A SG 11201910043PA SG 11201910043P A SG11201910043P A SG 11201910043PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compositions
- tetrachlorobis
- ruthenate
- tampa
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- BNIFVTPIXGUZCU-UHFFFAOYSA-N 1h-indazole Chemical compound C1=CC=C2C=NNC2=C1.C1=CC=C2C=NNC2=C1 BNIFVTPIXGUZCU-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT Iiiimmoimiolollmonolooloviimiflinomovom (10) International Publication Number WO 2018/204930 Al (51) International Patent Classification: A61K 31/416 (2006.01) A61K 33/24 (2006.01) A61K 31/555 (2006.01) (21) International Application Number: PCT/US2018/031436 (22) International Filing Date: 07 May 2018 (07.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/501,984 05 May 2017 (05.05.2017) US (71) Applicant: INTEZYNE TECHNOLOGIES, INC. [US/US]; 3720 Spectrum Blvd., Suite 104, Tampa, Florida 33612 (US). (72) Inventors; and (71) Applicants: VOJKOVSKY, Tomas [ /US]; 23 Shelby Lane, Palm Beach Gardens, Florida 33418 (US). SILL, Kevin [ /US]; 16308 Royal Park Ct., Tampa, Florida 33647 (US). CARIE, Adam [ /US]; 4206 Knob Lake Ct., Tampa, FL 33619 (US). (74) Agent: REID, Andrea L.C. et al.; One International Place, 100 Oliver Street, 40th Floor, Boston, Massachusetts 02110-2605 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: MANUFACTURE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] AND COMPOSITIONS = THEREOF 120 100 IT- 139 Drug Su b O cr O 1 \ \ 80 1 \ 1 \ \ 60 7 1 \\ \ \ \ 40d \ , 1 20 1 \\ \ 1 01 1 0 10 20 IT-139 2-8°C - -0- - IT-13918-22°C 30 40 50 60 Time (h) Figure 1 1-1 (57) : The present invention relates to the preparation of compositions comprising sodium trans-[tetrachlorobis(1H- ei • mdazole)ruthenate (III)]. Synthesis and formulation preparation is detailed. Impurity profiles are also discussed. Compositions herein C are useful for anti-cancer applications. [Continued on next page] WO 2018/204930 Al MIDEDIMOMMIDIRE10100101011fifilIMIHMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501984P | 2017-05-05 | 2017-05-05 | |
| PCT/US2018/031436 WO2018204930A1 (en) | 2017-05-05 | 2018-05-07 | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910043PA true SG11201910043PA (en) | 2019-11-28 |
Family
ID=64016742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910043P SG11201910043PA (en) | 2017-05-05 | 2018-05-07 | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10611787B2 (en) |
| EP (2) | EP4245305A3 (en) |
| JP (3) | JP7183253B2 (en) |
| CN (2) | CN111372939B (en) |
| AU (1) | AU2018263965B2 (en) |
| CA (1) | CA3062369A1 (en) |
| ES (1) | ES2959891T3 (en) |
| PL (1) | PL3618827T3 (en) |
| RU (1) | RU2019138773A (en) |
| SG (1) | SG11201910043PA (en) |
| WO (1) | WO2018204930A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019138773A (en) * | 2017-05-05 | 2021-06-08 | Интезайн Текнолоджис, Инк. | PRODUCTION OF TRANS- [TETRAHLORBIS (1H-INDAZOL) RUTENATE (III)] AND ITS COMPOSITIONS |
| US20230024119A1 (en) * | 2019-12-05 | 2023-01-26 | Bold Therapeutics, Inc. | Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers |
| WO2021195763A1 (en) * | 2020-03-30 | 2021-10-07 | Bold Therapeutics Inc. | Antiviral ruthenate(iii) therapeutics |
| JP2023549272A (en) * | 2020-11-18 | 2023-11-22 | ボールド セラピューティクス インコーポレイテッド | Use of trans-[tetrachloridobis(1H-indazole)sodium(III) ruthenate] to treat cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612291A1 (en) * | 1996-03-28 | 1997-10-02 | Bernhard K Prof Dr Dr Keppler | Pharmaceutical preparations containing ruthenium (III) complexes which have an anti-tumor effect |
| DE10103565B4 (en) * | 2001-01-26 | 2007-06-14 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Compositions containing a ruthenium (III) complex and a heterocycle |
| CA2686834C (en) | 2007-06-11 | 2014-05-27 | Bernhard Keppler | Method of manufacturing a ruthenium complex |
| CN102947320B (en) | 2010-06-22 | 2015-11-25 | 弗门尼舍有限公司 | Ruthenium base complex |
| JP6034288B2 (en) | 2010-07-18 | 2016-11-30 | ニーキ ファーマ インコーポレイテッド | Combination therapy using ruthenium complex |
| EP2976347B1 (en) | 2013-03-15 | 2022-01-19 | McFarland, Sherri Ann | Metal-based coordination complexes as photodynamic compounds and their use |
| CN103601759B (en) * | 2013-10-18 | 2015-08-19 | 武汉利宝瑞医药科技有限公司 | A kind of preparation method being used for the treatment of ruthenium (III) complex compound of tumour |
| US10342801B2 (en) * | 2015-06-23 | 2019-07-09 | Placon Therapeutics, Inc. | Platinum compounds, compositions, and uses thereof |
| RU2019138773A (en) * | 2017-05-05 | 2021-06-08 | Интезайн Текнолоджис, Инк. | PRODUCTION OF TRANS- [TETRAHLORBIS (1H-INDAZOL) RUTENATE (III)] AND ITS COMPOSITIONS |
-
2018
- 2018-05-07 RU RU2019138773A patent/RU2019138773A/en unknown
- 2018-05-07 EP EP23186755.7A patent/EP4245305A3/en active Pending
- 2018-05-07 AU AU2018263965A patent/AU2018263965B2/en active Active
- 2018-05-07 ES ES18794220T patent/ES2959891T3/en active Active
- 2018-05-07 SG SG11201910043P patent/SG11201910043PA/en unknown
- 2018-05-07 CA CA3062369A patent/CA3062369A1/en active Pending
- 2018-05-07 EP EP18794220.6A patent/EP3618827B1/en active Active
- 2018-05-07 CN CN201880043453.9A patent/CN111372939B/en active Active
- 2018-05-07 WO PCT/US2018/031436 patent/WO2018204930A1/en active Application Filing
- 2018-05-07 PL PL18794220.6T patent/PL3618827T3/en unknown
- 2018-05-07 CN CN202311350513.0A patent/CN117462558A/en active Pending
- 2018-05-07 JP JP2020511873A patent/JP7183253B2/en active Active
- 2018-05-07 US US15/973,370 patent/US10611787B2/en active Active
-
2020
- 2020-02-04 US US16/781,060 patent/US11040993B2/en active Active
-
2021
- 2021-05-26 US US17/330,822 patent/US11739111B2/en active Active
-
2022
- 2022-11-22 JP JP2022186393A patent/JP7433402B2/en active Active
-
2023
- 2023-07-20 US US18/355,945 patent/US20230357297A1/en active Pending
-
2024
- 2024-02-06 JP JP2024016340A patent/JP2024045436A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020518676A (en) | 2020-06-25 |
| PL3618827T3 (en) | 2024-01-22 |
| JP7433402B2 (en) | 2024-02-19 |
| EP3618827B1 (en) | 2023-07-26 |
| CA3062369A1 (en) | 2018-11-08 |
| AU2018263965A1 (en) | 2019-11-21 |
| US11739111B2 (en) | 2023-08-29 |
| EP3618827A4 (en) | 2020-09-02 |
| US10611787B2 (en) | 2020-04-07 |
| JP2023016867A (en) | 2023-02-02 |
| US20180327435A1 (en) | 2018-11-15 |
| CN117462558A (en) | 2024-01-30 |
| ES2959891T3 (en) | 2024-02-28 |
| CN111372939A (en) | 2020-07-03 |
| EP3618827A1 (en) | 2020-03-11 |
| CN111372939B (en) | 2023-11-07 |
| WO2018204930A1 (en) | 2018-11-08 |
| US11040993B2 (en) | 2021-06-22 |
| RU2019138773A (en) | 2021-06-08 |
| AU2018263965B2 (en) | 2024-02-29 |
| JP2024045436A (en) | 2024-04-02 |
| EP3618827C0 (en) | 2023-07-26 |
| US20200262855A1 (en) | 2020-08-20 |
| JP7183253B2 (en) | 2022-12-05 |
| RU2019138773A3 (en) | 2022-02-01 |
| EP4245305A3 (en) | 2023-10-04 |
| EP4245305A2 (en) | 2023-09-20 |
| US20230357297A1 (en) | 2023-11-09 |
| US20210277040A1 (en) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910043PA (en) | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof | |
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201908553SA (en) | Combination of isoindolinone derivatives with sgi-110 | |
| SG11201809494VA (en) | Pharmaceutical composition comprising eteplirsen | |
| SG11201907139UA (en) | Anti-fibrotic compounds | |
| SG11201809471UA (en) | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof | |
| SG11201903064SA (en) | Arsenic compositions | |
| SG11201809502YA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809899RA (en) | Method of treating hyperglycemia |